# Risk: __Lack of novel treatment options__ (PBN__Risk_2189)

## Property: has_RiskSubject

* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [healthcare providers](../Stakeholder/PBN__Stakeholder_121)

## Property: has_RiskISO_Impact

* [Health and care](../RiskISO/PBN__RiskISO_Purpose_0)

## Property: has_RiskSource

* [ting_digital_2020](../Article/PBN__Article_278)

## Property: has_RiskName

Limited treatment options and increased mortality rates.

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [Yes](../RiskGBN/PBN__RiskGBN_1)

## Property: has_RiskTechnology

* [artificial intelligence (ai)](../Technology/PBN__Technology_1714)

## Property: has_RiskOwner

* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskDescription

Limited availability of effective drugs for treating COVID-19.

## Property: has_RiskISO_Purpose

* [Well-being](../RiskISO/PBN__RiskISO_Impact_1)

## Property: has_RiskMitigation

* [Utilize AI algorithms for drug discovery and development of novel treatments.](../RiskMitigation/PBN__RiskMitigation_2860)

